Danielle M. Lauzon

PartnerCo-Chair, Life Sciences M&A, Boston Business Law Leader

+1 617 570 1955

Danielle M. Lauzon

Boston

+1 617 570 1955

Danielle Lauzon is a partner in Goodwin’s Technology and Life Sciences groups, co-chair of the Life Sciences M&A practice, and leader of the firm’s Business Law department in Boston. Danielle currently serves on Goodwin’s Partnership Committee.

Danielle advises privately-held and publicly-traded companies across the company life-cycle, including formation and founder matters, venture capital and growth equity financings, public offerings, mergers and acquisitions, joint ventures, carve-out transactions, SEC compliance and corporate governance. In addition, Danielle represents venture capital and private equity firms in connection with their investments in emerging growth and later-stage companies. Danielle’s practice focuses on the life sciences and healthcare sectors, including biotechnology, medical devices, digital health, healthcare IT, health & wellness and women’s health.

Danielle acts as co-chair of Goodwin’s PropSci practice which is focused on supporting the intersection of life sciences and real estate by providing clients integrated and innovative services that adapt along with their needs.

Experience

Danielle’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her representative transactions include:

Third Arc Bio in its $165 million Series A financing
Renagade Therapeutics in its $300 million Series A financing
ElevateBio in its $401 million Series D financing
ElevateBio in its $525 million Series C financing
ElevateBio in its $170 million Series B financing
Alltrna in $109 million Series B financing
Insight Partners in connection with its investments in Autobahn Therapeutics, Capacity Bio, Exsilio Therapeutics, ImmuneBridge, Profluent, Superluminal, Switch Therapeutics and Syrna Therapeutics
Cure Ventures in the $82 million Series A financing of Kenai Therapeutics
Laronde in its $440 million Series B financing
Instride Health in its $30 million Series B financing
FamilyWell Health in its $4.3 million Series Seed financing
Koneksa Health in its $45 million Series C financing
Koneksa Health in its $16 million Series B financing
.406 Ventures in its investments in Iora Health, Heartbeat Health, Wellist, Virtudent, Diana Health, Portrait Analytics, and Vivorcare
Flare Capital in its investments in Eden Health, Greater Good Health, Inbound Health, Oui Health and Positive Development
HLM Venture Partners in its investment in HealthEC
Aura Biosciences in its $80 million financing
Cullinan Oncology in its $131.2 million Series C financing
Unum Therapeutics in its $104.4 million private placement of common stock
Outcomes4Me in its Series Seed and Series A preferred stock financings
iTeos Therapeutics in its $125.3 million Series B financing
Allurion Technologies in its $27 million Series C financing
Omega Funds in its investments in Amunix Pharmaceuticals, Endeavor BioMedicines and Vanqua Bio
AbleTo, Inc. in its Series A, Series B, Series C, and Series D financings
Moderna Therapeutics in the closing of a $110 million financing round
Alector LLC in its Series A, Series B, Series C, and Series D financings
Unum Therapeutics in its $65 million Series B financing

Adicet Bio in its $100.0 million at-the-market offering
Adicet Bio in its $90.0 million public offering
Adicet Bio in its $87.5 million public offering
Adicet Bio in its $130 million public offering and concurrent $15 million private placement
Blueprint Medicines Corporation in its $325 million follow-on offering
Blueprint Medicines in its $345 million, $230 million and $125 million follow-on offerings
BELLUS Health in its $200 million public offering
BELLUS Health in its $40 million public offering
Aura Biosciences in its $99.0 million public offering
Aura Biosciences in its $80.4 million public offering
Aura Biosciences in its $75.6 million initial public offering
iTeos Therapeutics in its $201.1 million initial public offering
AlloVir, Inc. in its $317.7 million initial public offering
resTORbio, Inc. in its $97.8 million initial public offering
Cullinan Oncology in its $249.9 million initial public offering
Unum Therapeutics in its $69.2 million initial public offering and $5 million concurrent private placement
ProQR Therapeutics in its $75 million underwritten public offering
ProQR Therapeutics in its $20 million underwritten public offering and concurrent registered direct offering
ProQR Therapeutics N.V. in its $97.5 million initial public offering
Zafgen in its $60 million underwritten public offering
Aerpio Pharmaceuticals in its $40 million underwritten public offering and uplisting to Nasdaq
Aerpio Pharmaceuticals in its $75 million at-the-market program with Cantor Fitzgerald & Co.

Blueprint Medicines in its acquisition of Lengo Therapeutics
Allurion Technologies in its business combination with Compute Health Acquisition Corp.
Unum Therapeutics in its acquisition of KIQ and concurrent private placement
Aerpio Pharmaceuticals in its reverse merger with Aadi Biosciences and concurrent private placement
Zafgen in its definitive merger agreement with Chondrial Therapeutics
resTORbio, Inc. in its reverse merger with Adicet Bio
Semma Therapeutics in its $950 million sale to Vertex
Navitor Pharmaceuticals in connection with the sale of Anakuria Therapeutics by Janssen Pharmaceuticals
Onyx Pharmaceuticals in its $10.4 billion sale to Amgen
AMRI in its $1.7 billion (enterprise value) sale to affiliates of The Carlyle Group and GTCR LLC
AMRI in its $358 million acquisition of Euticals and $174 million acquisition of Gadea Pharmaceutical Group
Promedior, Inc. in its strategic agreement with Bristol-Myers Squibb
Picis Solutions in its sale to Ingenix, a subsidiary of UnitedHealth Group
Phase Forward in its sale to Oracle Corporation

Areas of Practice

Professional Activities

Danielle is a member of the Massachusetts and Boston Bar Associations.

Professional Experience

Prior to joining Goodwin, Danielle was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.

Credentials

Education

JD2000

Villanova University School of Law

(magna cum laude, Order of the Coif)

BA1997

University of Michigan

Admissions

Bars

Massachusetts

Recognition & Awards

Danielle is most recently recognized by Chambers USA 2025 in Massachusetts Private Equity: Venture Capital Investment and was previously recognized in 2024.

Danielle has been recognized by The Legal 500 US for her work in the life science industry. In 2023, The Legal 500 recognized her as a Next Generation Partner for her work in Venture Capital and Emerging Companies and in 2025, she was recognized as a Leading Partner. Massachusetts Lawyers Weekly named Danielle to its Top Women of Law list for 2021. From 2007 through 2021, she was recognized as a Massachusetts Super Lawyer "Rising Star" by Law & Politics and Boston magazine. In law school, Danielle was a member of the Villanova Law Review.

Danielle M. Lauzon

Experience

Private Financings

Public Offerings

Mergers & Acquisitions

Areas of Practice

Professional Activities

Professional Experience

Credentials

Education

JD2000

BA1997

Admissions

Bars

Recognition & Awards

Related Content

Navigating The New Normal: Life Sciences Real Estate is Going Viral — What Lenders Need to Know

Life Sciences Real Estate is Going Viral – What Lenders Need to Know

How Technology May be a Key X-Factor in the Real Estate Industry’s Road to Recovery

PTAB is Not Required to Dig Into the Record to Uncover Parties’ Arguments

Webinar Recording: PropSci Virtual Meeting

VIDEO: Goodwin Download Speaker Series: Striking a Work-Life Balance

VIDEO: Goodwin Download Speaker Series: Significant Change for Women Re-entering the Workforce?

VIDEO: Goodwin Download Speaker Series: For Women in Tech, Have We Come a Long Way?